Atrial fibrillation, cancer and anticancer drugs

Font, Jonaz; Milliez, Paul; Ouazar, Alexandre-Boudjema; Klok, Frederikus A.; Alexandre, Jonas

doi:10.1016/j.acvd.2023.02.005

Cited by 9 publications

(8 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sinus bradycardia is an important risk factor for prolonged QT interval and the development of lethal polymorphic ventricular tachycardia ( Roden, 2016 ; Zamorano et al, 2016 ). It is often underestimated clinically, because of its low incidence and the fact that most patients are asymptomatic; therefore, the focus should be on the potentially harmful effects of sinus bradycardia in cancer patients ( Font et al, 2023 ). Thalidomide causes sinus bradycardia (heart rate of 30–50 beats/min) in 53% of patients with multiple myeloma, heart rate as low as 30 beats/min in eight patients with symptoms of severe weakness and hypotension, and syncope in 12% of patients, one-third of whom were fitted with pacemakers ( Fahdi et al, 2004 ; Barlogie et al, 2006 ; Herrmann, 2020 ).…”

Section: Types Of Arrhythmias Caused By Chemotherapy Drugsmentioning

confidence: 99%

A review of chemotherapeutic drugs-induced arrhythmia and potential intervention with traditional Chinese medicines

Li,

Cheng,

Zhu

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Significant advances in chemotherapy drugs have reduced mortality in patients with malignant tumors. However, chemotherapy-related cardiotoxicity increases the morbidity and mortality of patients, and has become the second leading cause of death after tumor recurrence, which has received more and more attention in recent years. Arrhythmia is one of the common types of chemotherapy-induced cardiotoxicity, and has become a new risk related to chemotherapy treatment, which seriously affects the therapeutic outcome in patients. Traditional Chinese medicine has experienced thousands of years of clinical practice in China, and has accumulated a wealth of medical theories and treatment formulas, which has unique advantages in the prevention and treatment of malignant diseases. Traditional Chinese medicine may reduce the arrhythmic toxicity caused by chemotherapy without affecting the anti-cancer effect. This paper mainly discussed the types and pathogenesis of secondary chemotherapeutic drug-induced arrhythmia (CDIA), and summarized the studies on Chinese medicine compounds, Chinese medicine Combination Formula and Chinese medicine injection that may be beneficial in intervention with secondary CDIA including atrial fibrillation, ventricular arrhythmia and sinus bradycardia, in order to provide reference for clinical prevention and treatment of chemotherapy-induced arrhythmias.

show abstract

Section: Types Of Arrhythmias Caused By Chemotherapy Drugsmentioning

confidence: 99%

A review of chemotherapeutic drugs-induced arrhythmia and potential intervention with traditional Chinese medicines

Li,

Cheng,

Zhu

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…AF is much more common in cancer patients than in the general population (2-16%), and the highest incidence is reported in those after LC surgery-ranging from 6% to 32% [34][35][36]. Imperatori et al showed that almost 10% of patients after lobectomy had postoperative AF [36].…”

Section: Supraventricular Arrhythmias 41 Atrial Fibrillationmentioning

confidence: 99%

Cardiac Arrhythmias in Patients Treated for Lung Cancer: A Review

Hawryszko,

Sławiński,

Tomasik

et al. 2023

Cancers

View full text Add to dashboard Cite

Cardio-oncology currently faces one of the greatest challenges in the field of health care. The main goal of this discipline is to ensure that patients treated for cancer do not suffer or die from cardiovascular disease. The number of studies on the mechanisms of heart injury during cancer treatment is constantly increasing. However, there is insufficient data on heart rhythm disorders that may result from this treatment. This issue seems to be particularly important in patients with lung cancer, in whom anticancer therapy, especially radiotherapy, may contribute to the onset of cardiac arrhythmias. The observed relationship between cardiac dosimetry and radiotherapy-induced cardiotoxicity in lung cancer treatment may explain the increased mortality from cardiovascular causes in patients after chest irradiation. Further research is essential to elucidate the role of cardiac arrhythmias in this context. Conversely, recent reports have highlighted the application of stereotactic arrhythmia radioablation (STAR) in the treatment of ventricular tachycardia. This review of available studies on the epidemiology, pathogenesis, diagnosis, and treatment of arrhythmias in patients treated for lung cancer aims to draw attention to the need for regular cardiological monitoring in this group of patients. Improving cardiac care for patients with lung cancer has the potential to enhance their overall therapeutic outcomes.

show abstract

“…Воспаление может способствовать развитию ФП, изменяя электрофизиологические параметры предсердий напрямую (через нарушение регуляции кальциевых или других ионных каналов) и/или косвенно, способствуя ремоделированию предсердий [15]. Некоторые химиотерапевтические препараты вызывают нарушения в калиевых, натриевых и кальциевых каналах, что приводит к изменению потенциала действия и рефрактерного периода, благо-приятствует поддержанию ФП [4,9]. Более того, опухоль или метастазы, примыкающие к сердцу, могут напрямую вызывать ФП, сдавливая левое предсердие.…”

Section: механизмы фибрилляции предсердийunclassified

“…Наиболее известными группами химиотерапевтических препаратов, ассоциированными с возникновением ФП, являются алкилирующие агенты (цисплатин, циклофосфамид), антрациклины, анти-HER2-препараты (HER2 -human epidermal growth factor receptor 2, рецептор эпидермального фактора роста, тип 2), антиметаболиты (капецитабин, 5-фторурацил) и ингибиторы тирозинкиназы [30]. Частота раузития ФП у пациентов, получающих цисплатин, составляет 10-32 % [4,31], антрациклины -10 % [20], паклитаксел -1,0-1,7 % [32], мелфалан -6,5-16,7 % [16].…”

Section: вид полихимиотерапии и фибрилляция предсердийunclassified

“…Онкологические больные имеют более высокий риск развития ФП, чем население в целом. Распространенность данной патологии среди пациентов со злокачественными новообразованиями (ЗНО) высока: составляет около 20 % [2,3], а в ряде случаев может доходить до 30 % [4,5].…”

Section: Introductionunclassified

See 1 more Smart Citation

Atrial fibrillation and malignant neoplasms: state of the problem

Kostin,

Tsyrenov

2023

jour

View full text Add to dashboard Cite

Patients with malignant neoplasms have an increased risk of atrial fibrillation. Prevalence of this pathology among oncological patients is 20–30 %, and it significantly varies depending on tumor type, chemotherapy treatment and initial comorbid status. Atrial fibrillation and malignant neoplasms have similar risk factors. Researchers have identified several possible causes characteristic of these diseases, primarily, systemic inflammation. Some chemotherapies cause abnormalities in ionic channels of atrial cardiomyocytes which leads to changes in the action potential and refractory period, which promote maintenance of atrial fibrillation. The most known groups of chemotherapy drugs associated with atrial fibrillation are alkylating agents (cisplatin, cyclophosphamide), anthracyclines used in sarcoma treatment, as well as anti-HER2 drugs (HER2 – human epidermal growth factor receptor 2), antimetabolites (capecitabine, 5-fluorouracil) and tyrosine kinase inhibitors. However, pathophysiological mechanisms linking together atrial fibrillation and malignant neoplasms require further study.

show abstract

Atrial fibrillation, cancer and anticancer drugs

Cited by 9 publications

References 64 publications

A review of chemotherapeutic drugs-induced arrhythmia and potential intervention with traditional Chinese medicines

A review of chemotherapeutic drugs-induced arrhythmia and potential intervention with traditional Chinese medicines

Cardiac Arrhythmias in Patients Treated for Lung Cancer: A Review

Atrial fibrillation and malignant neoplasms: state of the problem

Contact Info

Product

Resources

About